Lilly to present new data on Byetta and Bydureon

Lilly and partners Alkermes and Amylin Pharmaceuticals are to present clinical trial data demonstrating the safety and efficacy of their diabetes drugs Byetta and Bydureon at a forthcoming conference.

The companies will be giving more than a dozen presentations at the annual meeting of the European Association for the Study of Diabetes in Stockholm between September 20th and 24th 2010, demonstrating the glycaemic control the drugs provide to type 2 diabetes patients, as well as assessing associated cardiovascular risks.

Bydureon is the proposed brand name for an investigational once-weekly treatment based on exenatide, the active ingredient of the approved and widely available Byetta therapy.

Dr Orville Kolterman, senior vice-president and chief medical officer at Amylin, said the studies will improve understanding of Byetta's benefits, while illustrating the potential of Bydureon.

He added: "These studies underscore our commitment to advancing diabetes treatment."

Lilly recently published its financial results for the second quarter of 2010, highlighting a nine per cent year-on-year revenue increase during the period.